['rheumatoid arthritis']
['placebo', 'upadacitinib']

        Inclusion Criteria:

          -  Diagnosis of rheumatoid arthritis (RA) for >= 3 months who also fulfill the 2010
             American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR)
             classification criteria for RA.

          -  Subjects have been receiving conventional synthetic disease-modifying anti-rheumatic
             drug (csDMARD) therapy >= 3 months and on a stable dose for >= 4 weeks prior to the
             first dose of study drug.

          -  Subject has >= 6 swollen joints (based on 66 joint counts) and >= 6 tender joints
             (based on 68 joint counts) at Screening and Baseline Visits.

          -  Subjects with prior exposure to at most one biological disease-modifying
             anti-rheumatic drug (bDMARD) may be enrolled (up to 20% of total number of subjects)
             after the required washout period. Specifically, prior to enrollment:

               1. Subjects with limited exposure to bDMARD (< 3 months) OR

               2. Subjects who are responding to bDMARD therapy but had to discontinue due to
                  intolerability (regardless of treatment duration).

        Exclusion Criteria:

          -  Prior exposure to any Janus kinase (JAK) inhibitor

          -  Subjects who are considered inadequate responders (lack of efficacy) to bDMARD
             therapy, after minimum 3 months treatment, as determined by the Investigator.

          -  History of any arthritis with onset prior to age 17 years or current diagnosis of
             inflammatory joint disease other than RA (including but not limited to gout, systemic
             lupus erythematosus, psoriatic arthritis, axial spondyloarthritis [SpA] including
             ankylosing spondylitis and non-radiographic axial SpA, reactive arthritis, overlap
             connective tissue diseases, scleroderma, polymyositis, dermatomyositis, fibromyalgia
             [currently with active symptoms]). Current diagnosis of secondary Sjogren's Syndrome
             is permitted.
      